Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02603952
Other study ID # D6000C00002
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 7, 2015
Est. completion date December 9, 2016

Study information

Verified date May 2018
Source MedImmune LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult participants with acute, uncomplicated influenza caused by Type A strains.


Description:

The MEDI8852 phase 2a study will evaluate the safety and tolerability of a single intravenous (IV) dose of MEDI8852 administered in conjunction with oseltamivir, the safety and tolerability of oseltamivir alone and the safety and tolerability of a single IV dose of MEDI8852 alone in adult participants with confirmed acute, uncomplicated influenza caused by Type A strains. Enrollment is planned in the United States, South Africa, and Australia.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date December 9, 2016
Est. primary completion date December 9, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 18 through 65 years at the time of screening.

- Symptomatic presumptive Influenza A infection with onset of symptoms less than or equal to (=) 5 days prior to MEDI8852 administration and defined as the presence of:

- Fever of greater than or equal to (=) 38.0 degrees Celsius (100.4 degrees Fahrenheit) at screening AND

- = 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or fatigue) AND

- = 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms)

- Influenza A infection confirmed with positive rapid antigen test

- Able to complete the follow-up period through Day 101 as required by protocol (including telephone follow-up for Days 11 to 101)

- Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 2 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study

Exclusion Criteria:

- Hospitalized subjects.

- Receipt of influenza antiviral therapy within the preceding 14 days.

- Receipt of immunoglobulin or blood products within 6 months prior to screening.

- Known immunodeficiency due to illness, including human immunodeficiency virus (HIV), or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.

- Current clinical evidence of pneumonia.

- Active bacterial infection requiring treatment with oral or parenteral antibiotics.

- History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 3 years.

- Any planned surgical procedure before completion of Day 101.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oseltamivir
75 mg capsules orally BID from Day 1 to Day 5.
MEDI8852
MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
Placebo
Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.

Locations

Country Name City State
South Africa Research Site Brandfort
South Africa Research Site Durban
South Africa Research Site Johannesburg
South Africa Research Site Pretoria
South Africa Research Site Pretoria
South Africa Research Site Pretoria
South Africa Research Site Pretoria
South Africa Research Site Thabazimbi
South Africa Research Site Welkom
United States Research Site Avon Indiana
United States Research Site Butte Montana
United States Research Site Canoga Park California
United States Research Site Clinton Utah
United States Research Site Hialeah Florida
United States Research Site Hialeah Florida
United States Research Site Hialeah Florida
United States Research Site Hickory North Carolina
United States Research Site Long Beach California
United States Research Site Los Angeles California
United States Research Site Miami Florida
United States Research Site Miami Florida
United States Research Site Miami Florida
United States Research Site Miami Lakes Florida
United States Research Site Muncie Indiana
United States Research Site New Orleans Louisiana
United States Research Site North Miami Beach Florida
United States Research Site San Antonio Texas
United States Research Site Shelby North Carolina
United States Research Site Smithfield Pennsylvania
United States Research Site Troy Michigan
United States Research Site Upland California

Sponsors (1)

Lead Sponsor Collaborator
MedImmune LLC

Countries where clinical trial is conducted

United States,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Any Solicited Influenza Symptoms From Day 1 Through Day 10 Solicited influenza symptoms included cough, nasal congestion, sore throat, aches and pains, fatigue (tiredness), headache, chills/sweats (feeling feverish). Day 1 (post-dose) through Day 10
Primary Number of Participants With Any Solicited Influenza Symptoms From Day 10 Through Day 13 Solicited influenza symptoms included cough, nasal congestion, sore throat, aches and pains, fatigue (tiredness), headache, chills/sweats (feeling feverish). Day 10 through Day 13
Primary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) An adverse event (AE) is any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent events were between administration of study drug and Day 28 that were absent before treatment or that worsened relative to pre-treatment state. Day 1 (post-dose) through Day 28
Primary Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were between administration of study drug and Day 101 that were absent before treatment or that worsened relative to pre-treatment state. Day 1 (post-dose) through Day 101
Primary Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESIs) An AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. An AESI was one of scientific and medical interest specific to understanding of the study drug and may have required close monitoring and rapid communication by the investigator to the sponsor. Treatment-emergent events were between administration of study drug and Day 101 that were absent before treatment or that worsened relative to pre treatment state. Day 1 (post-dose) through Day 101
Secondary Percentage of Participants With Influenza Viral Shedding as Measured by Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure influenza viral shedding from the nasopharyngeal swabs. Percentage of participants who shed influenza virus are reported. Baseline (Day 1) and Days 3, 5, 7, 9, 11, and 13
Secondary Quantitation of Influenza Viral Shedding as Measured by qRT-PCR qRT-PCR was used to measure influenza viral shedding from the nasopharyngeal swabs. Baseline (Day 1) and Days 3, 5, 7, 9, 11, and 13
Secondary Number of Days of Influenza Viral Shedding as Measured by qRT-PCR Number of days of viral shedding for participants who shed influenza virus is reported. qRT-PCR was used to measure influenza viral shedding from the nasopharyngeal swabs. From Baseline (Day 1) to Day 7; and Day 9 to Day 13
Secondary Percentage of Participants With Amino Acid Changes in MEDI8852 Binding Site Genotypic analysis was performed to identify all amino acid changes in MEDI8852 binding site between each baseline (Day1) sample and the participant's corresponding last sample sequenced. Percentage of participants with changes in the amino acid corresponding to MEDI8852 binding site is reported. Due to the fact that the percentage of participants with amino acid changes in MEDI8852 binding site was zero across all participant samples analyzed, no additional per arm analyses were performed. From Baseline (Day 1) to Day 13
Secondary Number of Participants With Viral Susceptibility to MEDI8852 as Determined by a Cell Based Microneutralization Assay Viral susceptibility to MEDI8852 was measured by a Madin-Darby canine kidney (MDCK) cell-based microneutralization assay (Virospot) for viruses recovered from baseline samples and viruses recovered from samples following treatment that contain amino acid changes within the MEDI8852 binding site. Participants with detectable levels (50% tissue culture infectious dose [TCID50]) of virus were considered susceptible and were reported. Due to the fact that the number of participants with viral susceptibility to MEDI8852 binding site was zero across all participant samples analyzed, no additional per arm analyses were performed. From Baseline (Day 1) to Day 13
Secondary Percentage of Participants With Virus Containing Known Oseltamivir Resistance-Associated Mutations Genotypic analysis was performed to identify all amino acid changes in neuraminidase (NA) gene between each baseline (Day1) sample and the participant's corresponding last sample sequenced. Percentage of participants with virus containing known oseltamivir resistance-associated mutations (change in the NA genes) is reported. Due to the fact that the percentage of participants with virus containing known oseltamivir resistance-associated mutation was zero across all participant samples analyzed, no additional per arm analyses were performed. From Baseline (Day 1) to Day 13
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A